Evolving neonatal steroid prescription habits and patient outcomes

Acta Paediatrica, International Journal of Paediatrics

Volumn 102, Issue 8, 2013, Pages 799-804

  Fortin Pellerin, Étienne ^a   Petersen, Claire ^b   Lefebvre, Francine ^c   Barrington, Keith J ^c   Janvier, Annie ^c  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Hydrocortisone; Neonatal intensive care; Neurodevelopment; Post natal steroids; Prematurity

Indexed keywords

HYDROCORTISONE; STEROID;

ARTICLE; CANADA; CHILD DEVELOPMENT; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG USE; FATALITY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HUMAN; INFANT; INFANT MORTALITY; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; NEWBORN CARE; OUTCOME ASSESSMENT; PARENT; POSTNATAL CARE; PREMATURITY; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; CAUSE OF DEATH; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HOSPITALS, UNIVERSITY; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; MALE; QUEBEC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879460337     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12285     Document Type: Article

References (22)

1. Barrington KJ,. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1: 1.
2. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999; 104: 15-21.
3. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177-81.
4. Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002; 109: 330-8.
5. Payne NR, Finkelstein MJ, Liu M, Kaempf JW, Sharek PJ, Olsen S,. NICU practices and outcomes associated with 9 years of quality improvement collaboratives. Pediatrics 2010; 125: 437-46.
6. Yoder BA, Harrison M, Clark RH,. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 2009; 124: 673-9.
7. Higgins S, Friedlich P, Seri I,. Hydrocortisone for hypotension and vasopressor dependence in preterm neonates: a meta-analysis. J Perinatol 2010; 30: 373-8.
8. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, and The DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics 2007; 119: 716-21.
9. Wilson-Costello D, Walsh MC, Langer JC, Guillet R, Laptook AR, Stoll BJ, et al. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics 2009; 123: e430-7. doi: 10.1542/peds.2008-1928.
10. Finer NN, Powers RJ, Ou CH, Durand D, Wirtschafter D, Gould JB, et al. Prospective evaluation of postnatal steroid administration: a 1-Year experience from the California perinatal quality care collaborative. Pediatrics 2006; 117: 704-13.
11. Derendorf H, Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M,. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 1991; 31: 473-6.
12. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC,. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005; 115: 655-61.
13. Watterberg K,. Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. Clin Perinatol 2012; 39: 47-59.
14. Jones R, Wincott E, Elbourne D, Grant A,. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics 1995; 96: 897-906.
15. Saarela T, Risteli J, Koivisto M,. Effects of short-term dexamethasone treatment on collagen synthesis and degradation markers in preterm infants with developing lung disease. Acta Paediatr 2003; 92: 588-94.
16. Tschanz SA, Makanya AN, Haenni B, Burri PH,. Effects of neonatal high-dose short-term glucocorticoid treatment on the lung: a morphologic and morphometric study in the rat. Pediatr Res 2003; 53: 72-80.
17. Okajima S, Matsuda T, Cho K, Matsumoto Y, Kobayashi Y, Fujimoto S,. Antenatal dexamethasone administration impairs normal postnatal lung growth in rats. Pediatr Res 2001; 49: 777-81.
18. Meadow W, Lee G, Lin K, Lantos J,. Changes in mortality for extremely low birth weight infants in the 1990s: implications for treatment decisions and resource use. Pediatrics 2004; 113: 1223-9.
19. Buchh B, Graham N, Harris B, Sims S, Corpuz M, Lantos J, et al. Neonatology has always been a bargain-even when we weren't very good at it!. Acta Paediatr 2007; 96: 659-63.
20. Berrington JE, Hearn RI, Bythell M, Wright C, Embleton ND,. Deaths in preterm infants: changing pathology over 2 decades. J Pediatr 2012; 160: e1.
21. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, and The DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006; 117: 75-83.
22. Yates HL, Newell SJ,. Minidex: very low dose dexamethasone (0.05 mg/kg/day) in chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2011; 96: F190-4.